DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological...
- Mechanism
- Curator reviewed
DP-b99 is a discovery product, rationally designed using D-Pharm’s proprietary technology, Membrane Active Chelators (MAC). Considerable evidence suggests that redistribution of metal ions and disturbances in metal ion homeostasis are key components in the cascade of events underlying cell damage in stroke. In the first hours post-stroke ion disturbances cause excitatory cell damage and in the days and weeks following they contribute to edema, inflammation and cell death. DP-b99 is a novel approach to neuroprotection based on selective modulation of calcium, zinc, copper and iron homeostasis in the vicinity of cell membranes.
- Primary indication
- Investigated for use/treatment in strokes and traumatic brain injuries.Curator reviewed
- Code names
- DP-b99
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with DP-b99, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account